Article Figures & Data
Figures
- FIGURE 1.
A 49-y-old man with NET of unknown origin for over 4 y. 68Ga-DOTATATE PET/CT (A) identified primary pancreatic lesion (arrow), whereas SSRS SPECT/CT (B) and WB DWI (C) did not. This lesion was noted only retrospectively (arrow) on dedicated abdominal CT (D) performed 4 y previously.
- FIGURE 2.
A 77-y-old woman with NET of unknown origin. 68Ga-DOTATATE PET/CT (A) showed multiple liver metastases and mesenteric nodule, whereas WB DWI (B) did not identify mesenteric nodule.
- FIGURE 3.
A 34-y-old woman with bronchial NET who underwent all 3 studies to evaluate response after chemotherapy. Patient had multiple liver lesions with marked uptake before chemotherapy. After chemotherapy, 68Ga-DOTATATE PET/CT (A) demonstrated marked uptake in one remaining liver metastasis, indicating lack of complete response to treatment, whereas SSRS SPECT/CT (B) and WB DWI (C) did not identify this lesion.
- FIGURE 4.
A 61-y-old woman with ileum NET. 68Ga-DOTATATE PET/CT (A) easily identified subcentimeter hepatic metastases, whereas SSRS SPECT/CT (B) and WB DWI (C) did not detect these lesions.
- FIGURE 5.
A 58-y-old woman with pancreatic NET. A 6-mm sacral metastasis was detected exclusively by 68Ga-DOTATATE PET/CT (A) and was confirmed retrospectively by dedicated MR imaging; WB DWI (B) did not detect this lesion.
Tables
P value Variable N/P 68Ga-DOTATATE PET/CT vs. SSRS SPECT/CT 68Ga-DOTATATE PET/CT vs. WB DWI All solid organs N 0.0253 0.0833 P Lungs and pleura N 1.0000 0.1573 P Liver N 0.1573 0.3173 P Pancreas N 0.0455 0.0455 P Gastrointestinal tract N 0.0455 0.0455 P All LNs N 0.5637 1.0000 P Cervical LNs N 1.0000 1.0000 P Thoracic LNs N 0.5637 0.0833 P Abdomen and pelvic LNs N 0.3137 0.3173 P All skeletal system N 0.0082 0.0082 P Bones of spine and pelvis N 0.0143 0.0455 P Thoracic bones N 0.0143 0.0143 P Bones of limbs N 0.0253 P 0.0455 Skull and skull base N 0.0455 P 0.0455 LNs = lymph nodes; N = negative; P = positive.
Percentage Organ type Imaging modality Sensitivity Specificity PPV NPV Accuracy Overall SSRS SPECT/CT 0.60 0.99 0.96 0.83 0.86 68Ga-DOTATATE PET/CT 0.96 0.97 0.94 0.98 0.97 WB DWI 0.72 1.00 1.00 0.88 0.91 All solid organs SSRS SPECT/CT 0.75 1.00 1.00 0.43 0.79 68Ga-DOTATATE PET/CT 1.00 0.67 0.94 1.00 0.95 WB DWI 0.88 1.00 1.00 0.60 0.89 Lung and pleura SSRS SPECT/CT 0.50 1.00 1.00 0.88 0.89 68Ga-DOTATATE PET/CT 0.50 1.00 1.00 0.88 0.89 WB DWI 1.00 1.00 1.00 1.00 1.00 Liver SSRS SPECT/CT 0.85 1.00 1.00 0.75 0.89 68Ga-DOTATATE PET/CT 1.00 1.00 1.00 1.00 1.00 WB DWI 0.92 1.00 1.00 0.86 0.95 Pancreas SSRS SPECT/CT 0.75 1.00 1.00 0.94 0.95 68Ga-DOTATATE PET/CT 1.00 0.80 0.57 1.00 0.84 WB DWI 0.75 1.00 1.00 0.94 0.95 Gastrointestinal tract SSRS SPECT/CT 0.50 1.00 1.00 0.94 0.95 68Ga-DOTATATE PET/CT 1.00 0.82 0.40 1.00 0.84 WB DWI 0.50 1.00 1.00 0.94 0.95 Lymph nodes SSRS SPECT/CT 0.85 1.00 1.00 0.75 0.89 68Ga-DOTATATE PET/CT 0.92 1.00 1.00 0.86 0.95 WB DWI 1.00 1.00 1.00 1.00 1.00 Musculoskeletal system SSRS SPECT/CT 0.46 1.00 1.00 0.46 0.63 68Ga-DOTATATE PET/CT 1.00 1.00 1.00 1.00 1.00 WB DWI 0.42 1.00 1.00 0.50 0.63 NPV = negative predictive value; PPV = positive predictive value.
Jump to section
Related Articles
Cited By...
- Management impact: effects on quality of life and prognosis in MEN1
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Diagnostic Imaging in Neuroendocrine Tumors